TORONTO, April 8 (Reuters) - Labopharm Inc’s lengthy struggle to get U.S. Food and Drug Administration approval for its once-daily version of the pain killer tramadol could be over in about four months, its president and chief executive, James Howard-Tripp, told Reuters on Tuesday.
